Major Depressive Disorder (MDD)HOMENCT07228468
Home-Based Transcranial Direct Current Stimulation In Major Depressive Disorder (HOME)
A study testing transcranial direct current stimulation (tDCS) in people with Major Depressive Disorder (MDD), run by King's College London at 6 sites in United Kingdom.
Trial summary
Depression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Major Depressive Disorder (MDD)
- What is being tested?
- transcranial direct current stimulation (tDCS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 438 participants
- Where
- 6 sitesUnited Kingdom
- Study dates
- 18 Nov 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or over
- Current episode of depression based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998)
- Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS
- Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment.
- Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment.
- Being under the care of GP
- Agreeable for GP to be regularly informed about study participation
- Able to provide written, informed consent
Who cannot join
- Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011)
- Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM-5 criteria as assessed in MINI
- Current daily use of medications that affect cortical excitability (e.g. benzodiazepines)
- Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023)
- History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation
- History of esketamine / ketamine for treatment of depression
Show all 14Show fewer
- History of psychosurgery for depression
- Having cognitive impairment (e.g. dementia)
- Current medical disorder or neurological disorder that may mimic mood disorder (e.g. hormonal disorder, unstable heart disease)
- Have any implant in the brain or neurocranial defect
- Have shrapnel or any ferromagnetic material in the head
- Have any active implantable medical device (e.g. pacemaker)
- If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study
- Concurrent enrolment in another interventional study
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
United Kingdom6 sites, 6 recruiting
- Not yet recruiting
Cardiff and Vale Health Board
Cardiff, CF24 4HQ
Neil Harrison
- Recruiting
South London and Maudsley NHS Foundation Trust
London, SE5 8AF
Cynthia Fu, MD, MSc, PhD
- Not yet recruiting
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
Newcastle, NE4 5PL
Stuart Watson
- Not yet recruiting
Northamptonshire Healthcare NHS Foundation Trust
Northampton, NN5 6UD
Chris Griffiths
- Not yet recruiting
Nottinghamshire Healthcare NHS Foundation Trust
Nottingham, NG7 2UH
Sudheer Lankappa
- Not yet recruiting
Hampshire and Isle of Wight Healthcare NHS Foundation Trust
Southampton, SO14 3DT
David Baldwin
About this study
Official title: Home-Based Transcranial Direct Current Stimulation in Major Depressive Disorder: a Multi-Centre, Two-Parallel Group, Superiority Randomised Controlled Trial
Depression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice. Furthermore, even following a full course of treatment with an antidepressant or talking therapy, over one third of patients continue to be unwell.
The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for major depression. The present research question is whether home-based tDCS is an effective treatment for major depression for adults with major depression.
Read more
Participants will be randomised to receive either a 10-week course of active tDCS treatment in addition to their standard care (Treatment as Usual), or to only receive Treatment as Usual. Participants will be followed up for 6-months after the start of the treatment began.
After the 6-month follow-up visit, all participants from both groups can choose to continue/start the tDCS treatment. There will be a final follow-up visit 3 months later (9 months from the original treatment start of the trial).
Read the detailed description
Current pharmacotherapy and psychotherapy treatments for major depressive disorder (MDD) often fall short in efficacy and patient satisfaction, highlighting a critical need for innovative, effective and acceptable treatment options. Transcranial direct current stimulation (tDCS) has emerged as a promising treatment, offering a non-invasive method to modulate brain activity and alleviate depressive symptoms that can be provided at home.
This trial builds on our work and aims to evaluate the effectiveness and cost-effectiveness of home-based tDCS as a treatment for MDD in the NHS. The trial is a multi-centre pragmatic RCT to evaluate the real-life clinical effectiveness and cost-effectiveness of tDCS combined with treatment as usual (TAU) as compared to TAU alone following a 10-week treatment period and at a 6-month follow up. Depressive symptoms will be measured by the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS). We will further assess impact on self-report depressive symptoms, anxiety symptoms, remission, acceptability and quality of life. We will conduct in-depth process evaluation, economic evaluation, and implementation work to investigate operational challenges of integrating home-based tDCS into existing NHS care pathways and to inform scalability in primary care settings.
438 Participants will be aged 18 years or over, diagnosed with MDD with at least moderate severity of depressive symptoms and medication free or taking stable antidepressant medication or in psychotherapy for at least 6 weeks before enrolment. Participants will be randomly assigned in a 1:1 ratio to either TAU or TAU+tDCS.
Participants randomised to the TAU treatment arm will continue with standard care including psychotherapy and/or antidepressant medication, as decided by participant and treating clinician. Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session.
The primary outcome is the difference in depressive symptoms between treatment arms at 10-week end of treatment as measured by MADRS and the key secondary outcome is the long term clinical effectiveness as measured by difference in depressive symptoms between treatment arms at 6-month follow up as measured by MADRS.
After the 6-month follow up, a 3-month extension follow up phase will give all participants the opportunity to use the tDCS device.
This research addresses an unmet need for new treatment options for MDD, thereby benefiting people with MDD, improving NHS care pathways, and expanding scientific knowledge.
- Conditions
- Major Depressive Disorder (MDD)
- Being tested
- transcranial direct current stimulation (tDCS)
- Keywords
- transcranial direct current stimulation, tDCS, major depression, MDD, major depressive disorder, brain stimulation
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcranial direct current stimulation (tDCS)Device
Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session.
| Study group | Role | What they receive |
|---|---|---|
| Treatment as usual (TAU) | No intervention | Treatment as usual will consist of standard care, such as psychotherapy and/or antidepressant medication or no treatment, as decided by participant and treating clinician. |
| transcranial direct current stimulation + treatment as usual (tDCS + TAU) | Experimental | In addition to receiving treatment as usual, participants randomized to receive tDCS will engage in a 10-week treatment protocol of active tDCS which participants will administer at home. Stimulation schedule is 5 sessions per week for 3 weeks followed by 3 sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS device is headset with bifrontal montage, anode at left dorsolateral prefrontal cortex (DLPFC) and cathode at right DLPFC (EEG positions F3 and F4, respectively). Stimulation is 2 mA for 30 minutes with a gradual ramp up over 30 seconds. Electrode area is 23 cm2. Receives: Device: transcranial direct current stimulation (tDCS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Montgomery-Åsberg Depression Rating Scale (MADRS)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 10 weeks
Secondary outcomes (11)
Montgomery-Åsberg Depression Rating Scale (MADRS)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 6 months
Hamilton Depression Rating Scale (HDRS)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 10 weeks
Hamilton Anxiety Rating Scale (HAMA)
To evaluate tDCS clinical effectiveness as the difference in anxiety symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 10 weeks
Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 10 weeks
Hamilton Depression Rating Scale (HDRS)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 6 months
Hamilton Anxiety Rating Scale (HAMA)
To evaluate tDCS clinical effectiveness as the difference in anxiety symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 6 months
Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of the 6 month follow-up period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
Measured: 6 months
Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response
To evaluate treatment response at the 10-week end of treatment period between treatment arms. Treatment response is defined as an improvement of 50% or more from baseline MADRS score.
Measured: 10 weeks
Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission
To evaluate treatment remission at the 10-week end of treatment period between treatment arms. Treatment remission is defined as a MADRS score of 10 or less.
Measured: 10 weeks
Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response
To evaluate treatment response at the 6 month end of follow-up period between treatment arms. Treatment response is defined as an improvement of 50% or more from baseline MADRS score.
Measured: 6 months
Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission
To evaluate treatment remission at the 6 month follow-up period between treatment arms. Treatment remission is defined as a MADRS score of 10 or less.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study start18 Nov 2025
- Primary completion15 May 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Major Depressive Disorder (MDD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized to receive active transcranial direct current stimulation (tDCS) OR treatment as usual (TAU).
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 438 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- Nottinghamshire Healthcare NHS Trust, Cardiff and Vale University Health Board, Northumberland, Tyne and Wear NHS Foundation Trust, Northamptonshire Healthcare NHS Foundation Trust, South London and Maudsley NHS Foundation Trust, Southern Health NHS Foundation Trust
- Responsible party
- Sponsor
- Investigators
- Cynthia Fu, MD, PhD, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07228468
- Sponsor's protocol ID
- NIHR165425
- Other IDs
- NIHR165425
- Acronym
- HOME
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymised data will be made available on request.
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home-Based Transcranial Direct Current Stimulation in Major Depressive Disorder: a Multi-Centre, Two-Parallel Group, Superiority Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT07228468
- Acronym / sponsor ID
- HOME / NIHR165425
- Conditions
- Major Depressive Disorder (MDD)
- Keywords
- transcranial direct current stimulation, tDCS, major depression, MDD, major depressive disorder, brain stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 438 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- Nottinghamshire Healthcare NHS Trust, Cardiff and Vale University Health Board, Northumberland, Tyne and Wear NHS Foundation Trust, Northamptonshire Healthcare NHS Foundation Trust, South London and Maudsley NHS Foundation Trust, Southern Health NHS Foundation Trust
- Study start
- 18 Nov 2025 (actual)
- Primary completion
- 15 May 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Depression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice. Furthermore, even following a full course of treatment with an antidepressant or talking therapy, over one third of patients continue to be unwell.
The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for major depression. The present research question is whether home-based tDCS is an effective treatment for major depression for adults with major depression.
Participants will be randomised to receive either a 10-week course of active tDCS treatment in addition to their standard care (Treatment as Usual), or to only receive Treatment as Usual. Participants will be followed up for 6-months after the start of the treatment began.
After the 6-month follow-up visit, all participants from both groups can choose to continue/start the tDCS treatment. There will be a final follow-up visit 3 months later (9 months from the original treatment start of the trial).
Detailed description
Current pharmacotherapy and psychotherapy treatments for major depressive disorder (MDD) often fall short in efficacy and patient satisfaction, highlighting a critical need for innovative, effective and acceptable treatment options. Transcranial direct current stimulation (tDCS) has emerged as a promising treatment, offering a non-invasive method to modulate brain activity and alleviate depressive symptoms that can be provided at home.
This trial builds on our work and aims to evaluate the effectiveness and cost-effectiveness of home-based tDCS as a treatment for MDD in the NHS. The trial is a multi-centre pragmatic RCT to evaluate the real-life clinical effectiveness and cost-effectiveness of tDCS combined with treatment as usual (TAU) as compared to TAU alone following a 10-week treatment period and at a 6-month follow up. Depressive symptoms will be measured by the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS). We will further assess impact on self-report depressive symptoms, anxiety symptoms, remission, acceptability and quality of life. We will conduct in-depth process evaluation, economic evaluation, and implementation work to investigate operational challenges of integrating home-based tDCS into existing NHS care pathways and to inform scalability in primary care settings.
438 Participants will be aged 18 years or over, diagnosed with MDD with at least moderate severity of depressive symptoms and medication free or taking stable antidepressant medication or in psychotherapy for at least 6 weeks before enrolment. Participants will be randomly assigned in a 1:1 ratio to either TAU or TAU+tDCS.
Participants randomised to the TAU treatment arm will continue with standard care including psychotherapy and/or antidepressant medication, as decided by participant and treating clinician. Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session.
The primary outcome is the difference in depressive symptoms between treatment arms at 10-week end of treatment as measured by MADRS and the key secondary outcome is the long term clinical effectiveness as measured by difference in depressive symptoms between treatment arms at 6-month follow up as measured by MADRS.
After the 6-month follow up, a 3-month extension follow up phase will give all participants the opportunity to use the tDCS device.
This research addresses an unmet need for new treatment options for MDD, thereby benefiting people with MDD, improving NHS care pathways, and expanding scientific knowledge.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomized to receive active transcranial direct current stimulation (tDCS) OR treatment as usual (TAU).
| Arm | Type | Receives |
|---|---|---|
| Treatment as usual (TAU) | No intervention | –Treatment as usual will consist of standard care, such as psychotherapy and/or antidepressant medication or no treatment, as decided by participant and treating clinician. |
| transcranial direct current stimulation + treatment as usual (tDCS + TAU) | Experimental | Device: transcranial direct current stimulation (tDCS)In addition to receiving treatment as usual, participants randomized to receive tDCS will engage in a 10-week treatment protocol of active tDCS which participants will administer at home. Stimulation schedule is 5 sessions per week for 3 weeks followed by 3 sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS device is headset with bifrontal montage, anode at left dorsolateral prefrontal cortex (DLPFC) and cathode at right DLPFC (EEG positions F3 and F4, respectively). Stimulation is 2 mA for 30 minutes with a gradual ramp up over 30 seconds. Electrode area is 23 cm2. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adults aged 18 years or over
- Current episode of depression based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998)
- Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS
- Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment.
- Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment.
Key exclusion criteria (14 listed)
- Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011)
- Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM-5 criteria as assessed in MINI
- Current daily use of medications that affect cortical excitability (e.g. benzodiazepines)
- Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023)
- History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcranial direct current stimulation (tDCS)Participants randomised to the tDCS treatment arm will use a tDCS device which is a headset with the anode positioned over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC (EEG positions F3 and F4, respectively). Treatment protocol consists of 5 tDCS sessions per week for 3 weeks followed by 3 tDCS sessions per week for 7 weeks, for a total of 36 sessions in 10 weeks. tDCS stimulation is 2 mA for 30 minutes with gradual ramp up over 30 seconds at the start and end of each session. | Device | transcranial direct current stimulation + treatment as usual (tDCS + TAU) |
Primary outcome
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time frame: 10 weeks
To evaluate tDCS clinical effectiveness as the difference in depressive symptom severity at end of 10-week treatment period between two treatment arms: those receiving treatment as usual (TAU) alone and those receiving TAU plus tDCS
11 secondary outcomes
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time frame: 6 months
Hamilton Depression Rating Scale (HDRS)
Time frame: 10 weeks
Hamilton Anxiety Rating Scale (HAMA)
Time frame: 10 weeks
Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)
Time frame: 10 weeks
Hamilton Depression Rating Scale (HDRS)
Time frame: 6 months
Hamilton Anxiety Rating Scale (HAMA)
Time frame: 6 months
Montgomery-Åsberg Depression Rating Scale-Self Report (MADRS-S)
Time frame: 6 months
Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response
Time frame: 10 weeks
Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission
Time frame: 10 weeks
Montgomery-Åsberg Depression Rating Scale (MADRS) clinical response
Time frame: 6 months
Montgomery-Åsberg Depression Rating Scale (MADRS) treatment remission
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Individual participant dataSharing planned: Yes. Anonymised data will be made available on request.
Related trials for Major Depressive Disorder (MDD)
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
Not yet recruiting
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cynthia Fu, MD, PhD principal investigator
King's College London
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcranial direct current stimulation (tDCS) in people with Major Depressive Disorder (MDD), run by King's College London at 6 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cynthia Fu (020 7848 0002, cynthia.fu@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Montgomery-Åsberg Depression Rating Scale (MADRS) (time frame: 10 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.